Expansion into Non-Oncology Indications: The Critical Role of CDMO Partners
25 Feb 2025
Cell Therapy Development
)
- What are the key drivers behind the growing interest in non-oncological gene therapies and Which non-oncological therapeutic areas (e.g., rare diseases, hematology, neurology) present the most significant opportunities, and why?
- What unique technical challenges arise when developing gene /gene therapies for non-oncology indications, such as tissue-specific delivery or vector engineering?
- What are the most significant cost and scalability barriers in this space, and how can CDMOs help address them?
- What innovations in analytical testing or process optimization are CDMOs bringing to ensure the success of non-oncological gene therapies?
- What emerging technologies (e.g., non-viral delivery, CRISPR-based in vivo editing, universal cell platforms) will shape the future of CDMO partnerships in gene and cell therapies?
- What innovations in logistics and cryopreservation are needed to support global deployment of cell therapies in non-oncology indications?
